A pH/Enzyme-responsive tumor-specific delivery system for doxorubicin

Biomaterials

Volumn 31, Issue 24, 2010, Pages 6309-6316

  Dong, Lei ^a   Xia, Suhua ^a   Wu, Ke ^a   Huang, Zhen ^a   Chen, Huan ^a   Chen, Jiangning ^a   Zhang, Junfeng ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Cardiotoxicity; Doxorubicin; Gelatinase; PH enzyme responsive

Indexed keywords

ANTHRACYCLINES; ANTICANCER ACTIVITIES; BIODISTRIBUTIONS; CARDIOTOXICITY; CODIGESTION; DELIVERY SYSTEMS; DOXORUBICIN; DRUG CONCENTRATION; GELATINASE; HIGH DOSE; IN-VIVO TESTS; NANOCOMPLEXES; NANOSCALE COMPLEXES; PH SENSITIVE; SELF-ASSEMBLED; TUMOR HOMOGENATE; TUMOR TISSUES;

DYES; LIVER;

TUMORS;

ALGINIC ACID; ANTHRACYCLINE; CATIONIC GELATIN; CPG OLIGODEOXYNUCLEOTIDE; DEOXYRIBONUCLEASE I; DNA FRAGMENT; DOXORUBICIN; ENZYME; GELATIN; GELATINASE; NANOMATERIAL; POLYAT DNA; POLYGC DNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER TISSUE; CARDIOTOXICITY; CONTROLLED STUDY; DNA DRUG COMPLEX; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; DRUG TISSUE LEVEL; FEMALE; GC RICH SEQUENCE; IN VIVO STUDY; INTERCALATION COMPLEX; LIVER HOMOGENATE; MORTALITY; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; SUPERNATANT; TISSUE HOMOGENATE; ANIMAL; ANTIBODY SPECIFICITY; DRUG EFFECTS; METABOLISM; NEOPLASM; PROCEDURES; SPECTROFLUOROMETRY; TISSUE DISTRIBUTION; TOXICITY; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DEOXYRIBONUCLEASE I; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; GELATINASES; HYDROGEN-ION CONCENTRATION; MICE; NANOSTRUCTURES; NEOPLASMS; ORGAN SPECIFICITY; SPECTROMETRY, FLUORESCENCE; TISSUE DISTRIBUTION;

EID: 77953650864     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.04.049     Document Type: Article

References (25)

1. Yoshikawa K., Kitaoka H. Prolonged intra-aortic infusion therapy with anti-tumor agents for advanced cancer of the stomach, colon and rectum. Jpn J Surg 1971, 1:256-262.
2. Ganz W.I., Sridhar K.S., Forness T.J. Detection of early anthracycline cardiotoxicity by monitoring the peak filling rate. Am J Clin Oncol 1993, 16:109-112.
3. Haley B., Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol 2008, 26:57-64.
4. Kiyomiya K., Matsuo S., Kurebe M. Mechanism of specific nuclear transport of adriamycin: the mode of nuclear translocation of adriamycin-proteasome complex. Cancer Res 2001, 61:2467-2471.
5. Bodley A., Liu L.F., Israel M., Seshadri R., Koseki Y., Giuliani F.C., et al. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. Cancer Res 1989, 49:5969-5978.
6. Eliyahu H., Barenholz Y., Domb A.J. Polymers for DNA delivery. Molecules 2005, 10:34-64.
7. Emonard H., Grimaud J.A. Matrix metalloproteinases: a review. Cell Mol Biol 1990, 36:131-153.
8. Watanabe Y., Haruyama T., Akaike T. Liver-derived matrix metalloproteinase-9 (gelatinase B) recruits progenitor cells from bone marrow into the blood circulation. Biol Pharm Bull 2003, 26:564-568.
9. Matsumoto G., Kushibiki T., Kinoshita Y., Lee U., Omi Y., Kubota E., et al. Cationized gelatin delivery of a plasmid DNA expressing small interference RNA for VEGF inhibits murine squamous cell carcinoma. Cancer Sci 2006, 97:313-321.
10. Eklund A. On the determination of available lysine in casein and rapeseed protein concentrates using 2,4,6-trinitrobenzenesulphonic acid (TNBS) as a reagent for free epsilon amino group of lysine. Anal Biochem 1976, 70:434-439.
11. Weisblum B., Haenssler E. Fluorometric properties of the bibenzimidazole derivative Hoechst 33258, a fluorescent probe specific for AT concentration in chromosomal DNA. Chromosoma 1974, 46:255-260.
12. Jong J., Guérand W.S., Schoofs P.R., Bast A., van der Vijgh W.J. Simple and sensitive quantification of anthracyclines in mouse atrial tissue using high-performance liquid chromatography and fluorescence detection. J Chromatogr 1991, 570:209-216.
13. Trouet A., Campeneere D.D. Daunorubicin-DNA and doxorubicin-DNA: a review of experimental and clinical data. Cancer Chemother Pharmacol 1979, 2:77-79.
14. Trouet A., Sokal G. Clinical studies with daunorubicin-DNA and adriamycin-DNA complexes: a review. Cancer Treat Rep 1979, 63:895-898.
15. Dorr R.T., Shipp N.G., Lee K.M. Comparison of cytotoxicity in heart cells and tumor cells exposed to DNA intercalating agents in vitro. Anticancer Drugs 1991, 2:27-33.
16. Paik W.K., Kim S. Comparison of the acetylation of proteins and nucleic acids. Biochem J 1970, 116:611-615.
17. Tranchant I., Thompson B., Nicolazzi C., Mignet N., Scherman D. Physicochemical optimisation of plasmid delivery by cationic lipids. J Gene Med 2004, 6:S24-S35.
18. Wagner E. Strategies to improve DNA polyplexes for in vivo gene transfer: will ″ artificial viruses″ be the answer?. Pharm Res 2004, 21:8-14.
19. Paleos C.M., Tziveleka L.A., Sideratou Z., Tsiourvas D. Gene delivery using functional dendritic polymers. Expert Opin Drug Deliv 2009, 6:27-38.
20. Kushibiki T., Tomoshige R., Fukunaka Y., Kakemi M., Tabata Y. In vivo release and gene expression of plasmid DNA by hydrogels of gelatin with different cationization extents. J Control Release 2003, 90:207-216.
21. Ganea E., Trifan M., Laslo A.C., Putina G., Cristescu C. Matrix metalloproteinases: useful and deleterious. Biochem Soc Trans 2007, 35:689-691.
22. Deryugina E.I., Quigley J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006, 25:9-34.
23. Ferreira A.L., Matsubara L.S., Matsubara B.B. Anthracycline-induced cardiotoxicity. Cardiovasc Hematol Agents Med Chem 2008, 6:278-281.
24. Combs A.B., Acosta D. Toxic mechanisms of the heart: a review. Toxicol Pathol 1990, 18:583-596.
25. Ferrans V.J. Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat Rep 1978, 62:955-961.